Crinetics Approach

News Releases

News Releases

July 17, 2018
Crinetics Pharmaceuticals Announces Pricing of Initial Public Offering

SAN DIEGO , July 17, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the

June 18, 2018
Crinetics Pharmaceuticals Appoints Alan Krasner, M.D., as Chief Medical Officer
SAN DIEGO – June 18, 2018  – Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Alan S. Krasner, M.D.
March 13, 2018
Crinetics Pharmaceuticals Completes $63.5 Million Series B Financing
SAN DIEGO – March 13, 2018  – Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced it has completed a Series B financing which raised $63.5 million in new funds.
March 12, 2018
Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO 2018
SAN DIEGO – March 12, 2018  – Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced an oral presentation and two poster presentations relating to the company’s drug development candidates.